CD226 and neoplasm: In preclinical models, co-targeting PD-1 and GITR improves anti-tumor efficacy [43], possibly by restoring TIGIT/CD226 balance and preventing SHP2-mediated dephosphophorylation of the CD226 intracellular domain [44].